LT3571225T - Patobulintos serumo albumino rišamosios medžiagos - Google Patents

Patobulintos serumo albumino rišamosios medžiagos

Info

Publication number
LT3571225T
LT3571225T LTEPPCT/EP2018/051083T LTEP2018051083T LT3571225T LT 3571225 T LT3571225 T LT 3571225T LT EP2018051083 T LTEP2018051083 T LT EP2018051083T LT 3571225 T LT3571225 T LT 3571225T
Authority
LT
Lithuania
Prior art keywords
serum albumin
improved serum
albumin binders
binders
improved
Prior art date
Application number
LTEPPCT/EP2018/051083T
Other languages
English (en)
Lithuanian (lt)
Inventor
Stephanie Staelens
Soren Steffensen
Erika Morizzo
An Cerdobbel
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of LT3571225T publication Critical patent/LT3571225T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/EP2018/051083T 2017-01-17 2018-01-17 Patobulintos serumo albumino rišamosios medžiagos LT3571225T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762446988P 2017-01-17 2017-01-17
PCT/EP2018/051083 WO2018134235A1 (en) 2017-01-17 2018-01-17 Improved serum albumin binders

Publications (1)

Publication Number Publication Date
LT3571225T true LT3571225T (lt) 2024-11-11

Family

ID=61521465

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/051083T LT3571225T (lt) 2017-01-17 2018-01-17 Patobulintos serumo albumino rišamosios medžiagos

Country Status (21)

Country Link
US (2) US11414481B2 (enExample)
EP (3) EP4442709A3 (enExample)
JP (3) JP7219220B2 (enExample)
KR (2) KR102662499B1 (enExample)
CN (2) CN110191896B (enExample)
AU (2) AU2018209151B2 (enExample)
BR (1) BR112019014599A2 (enExample)
CA (1) CA3050575A1 (enExample)
DK (1) DK3571225T3 (enExample)
ES (1) ES2991459T3 (enExample)
FI (1) FI3571225T3 (enExample)
HR (1) HRP20241469T1 (enExample)
HU (1) HUE068790T2 (enExample)
IL (2) IL267894B2 (enExample)
LT (1) LT3571225T (enExample)
MX (2) MX2019008496A (enExample)
PT (1) PT3571225T (enExample)
RS (1) RS66117B1 (enExample)
SG (2) SG11201906264YA (enExample)
SI (1) SI3571225T1 (enExample)
WO (1) WO2018134235A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NZ780183A (en) * 2011-06-23 2024-12-20 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN117164710A (zh) 2016-12-07 2023-12-05 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
SG10202108973SA (en) * 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
ES2991459T3 (es) * 2017-01-17 2024-12-03 Ablynx Nv Ligantes de albúmina sérica mejorados
CA3163764A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
CN114981300B (zh) 2019-12-06 2025-10-31 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
AU2020400938A1 (en) 2019-12-09 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
EP4126971A1 (en) 2020-03-30 2023-02-08 Ablynx N.V. Method for the production and purification of multivalent immunoglobulin single variable domains
CA3195687A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
WO2022129637A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
KR20230123497A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
IL303783A (en) 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
EP4448574A1 (en) 2021-12-17 2024-10-23 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
US20240109965A1 (en) 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor
JP2025526384A (ja) 2022-07-27 2025-08-13 アブリンクス エン.ヴェー. 新生児型Fc受容体の特異的エピトープに結合するポリペプチド
WO2024084203A1 (en) 2022-10-18 2024-04-25 Isogenica Limited Single domain antibodies binding to albumin
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
AU2024207151A1 (en) 2023-01-09 2025-06-19 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
TW202444757A (zh) 2023-03-14 2024-11-16 美商奧迪希治療公司 抗cd25抗原結合蛋白及其用途
TW202448951A (zh) 2023-05-17 2024-12-16 美商奧迪希治療公司 經修飾之單域抗體
KR102822958B1 (ko) * 2023-05-23 2025-06-20 대한민국(해양경찰청 해양경찰연구센터장) 고래 불법포획 감식용 신속진단키트
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
TW202515917A (zh) 2023-06-29 2025-04-16 美商奧迪希治療公司 抗trailr2抗原結合蛋白及其用途
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
US20250236673A1 (en) 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025217488A1 (en) * 2024-04-12 2025-10-16 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
US6742038B2 (en) 2000-04-07 2004-05-25 Danger, Inc. System and method of linking user identification to a subscriber identification module
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
KR20070086896A (ko) 2004-12-02 2007-08-27 도만티스 리미티드 항­il­1r1 단일 도메인 항체 및 치료적 용도
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
EP1957537A2 (en) 2005-12-01 2008-08-20 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
KR20080077238A (ko) 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
WO2010035012A1 (en) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
BR112012001681A2 (pt) 2009-07-16 2019-09-24 Graxo Group Ltd domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
BR112012007374A2 (pt) 2009-09-30 2019-09-24 Glaxo Group Ltd composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
KR20130055663A (ko) 2010-08-20 2013-05-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 개선된 항-혈청 알부민 결합 변이체
US11644471B2 (en) * 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NZ780183A (en) 2011-06-23 2024-12-20 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP3363813A1 (en) * 2011-06-23 2018-08-22 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
US20150344568A1 (en) * 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012174741A1 (en) 2011-06-24 2012-12-27 Google Inc. Determining cross-language query suggestion based on query translations
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US20130129727A1 (en) * 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
WO2014037419A1 (en) 2012-09-04 2014-03-13 Vib Vzw Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US20140186365A1 (en) * 2013-01-03 2014-07-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
PT3248986T (pt) 2014-05-16 2022-04-05 Ablynx Nv Domínios variáveis de imunoglobulina
WO2016118733A1 (en) 2015-01-21 2016-07-28 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
EP3611192B1 (en) 2015-05-13 2025-03-05 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
EP3974449A1 (en) * 2015-11-13 2022-03-30 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
CA3006398A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
CN117164710A (zh) 2016-12-07 2023-12-05 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
SG10202108973SA (en) * 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
ES2991459T3 (es) 2017-01-17 2024-12-03 Ablynx Nv Ligantes de albúmina sérica mejorados
AR133903A1 (es) * 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes

Also Published As

Publication number Publication date
BR112019014599A2 (pt) 2020-03-03
FI3571225T3 (fi) 2024-10-31
KR102662499B1 (ko) 2024-05-02
KR20240013861A (ko) 2024-01-30
AU2018209151B2 (en) 2025-02-27
RU2019125831A (ru) 2021-02-19
RS66117B1 (sr) 2024-11-29
RU2019125831A3 (enExample) 2021-03-09
SI3571225T1 (sl) 2025-03-31
SG10202108972RA (en) 2021-09-29
MX2019008496A (es) 2019-09-18
EP3571225A1 (en) 2019-11-27
HUE068790T2 (hu) 2025-01-28
IL267894B2 (en) 2024-10-01
JP2025026992A (ja) 2025-02-26
IL312292A (en) 2024-06-01
IL267894A (en) 2019-09-26
AU2018209151A1 (en) 2019-07-25
WO2018134235A8 (en) 2024-03-21
MX2023005374A (es) 2023-05-22
JP7628996B2 (ja) 2025-02-12
ES2991459T3 (es) 2024-12-03
JP2020515518A (ja) 2020-05-28
JP2023025232A (ja) 2023-02-21
EP4442709A3 (en) 2024-12-25
HRP20241469T1 (hr) 2025-01-03
CA3050575A1 (en) 2018-07-26
WO2018134235A1 (en) 2018-07-26
EP4442707A3 (en) 2024-12-25
EP4442709A2 (en) 2024-10-09
EP4442707A2 (en) 2024-10-09
CN110191896A (zh) 2019-08-30
JP7219220B2 (ja) 2023-02-07
US20190367597A1 (en) 2019-12-05
US20230060574A1 (en) 2023-03-02
CN117285623A (zh) 2023-12-26
SG11201906264YA (en) 2019-08-27
DK3571225T3 (da) 2024-11-04
IL267894B1 (en) 2024-06-01
US11414481B2 (en) 2022-08-16
EP3571225B1 (en) 2024-08-07
CN110191896B (zh) 2023-09-29
PT3571225T (pt) 2024-11-05
AU2025203430A1 (en) 2025-06-05
KR20190104608A (ko) 2019-09-10

Similar Documents

Publication Publication Date Title
IL267894A (en) Improved serum albumin binding agents
IL267897A (en) Improved serum albumin binding agents
SI3583125T1 (sl) Fuzijski proteini z albumin-vezavno domeno
ZA201804317B (en) Altered april binding antibodies
ZA201804601B (en) Psma binding antibody and uses thereof
HUE059510T2 (hu) Kötõanyag rendszer
PL3246370T3 (pl) Bezpośrednio przylegający, przezroczysty, zgrzewany wiążący środek do powlekania i zamykania przezroczystych folii z tworzywa sztucznego
CA3278826A1 (en) Her-2 binding antibodies
GB201610063D0 (en) Binders
ZA201901862B (en) Modified factor h binding protein
ZA201906821B (en) Anti-jagged1 antigen binding proteins
IL267318A (en) link test
GB201615588D0 (en) TSLP Binding Proteins
GB201614627D0 (en) Antigen binding proteins
HK1261097A1 (en) Improved serum albumin binders
GB201715149D0 (en) IL-ß binding antibody
GB201802995D0 (en) File serving
IL256197A (en) Binding folder
ZA201707980B (en) Binding folder
PH32016001013S1 (en) Clip binder